Ming-Hsien Chou1, Jong-Yi Wang2, Cheng-Li Lin3, Wei-Sheng Chung4. 1. Department of Public Health, China Medical University, Taichung, Taiwan; Department of Physical Medicine and Rehabilitation, Taichung Armed Forces General Hospital, Taichung, Taiwan; Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, Taipei, Taiwan; Section of Physical Medicine and Rehabilitation, School of Medicine, National Defense Medical Center, Taipei, Taiwan. 2. Department of Public Health, China Medical University, Taichung, Taiwan; Department of Health Services Administration, China Medical University, Taichung, Taiwan. 3. Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan. 4. Department of Health Services Administration, China Medical University, Taichung, Taiwan; Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung, Taiwan; Department of Healthcare Administration, Central Taiwan University of Science and Technology, Taichung, Taiwan. Electronic address: chung.w53@msa.hinet.net.
Abstract
BACKGROUND: Patients with rheumatoid arthritis (RA) exhibit an increased risk of dementia. Disease-modifying antirheumatic drugs (DMARDs) are commonly used to slow RA progression, but studies investigating the relationship between DMARDs and dementia in patients with RA are lacking. We investigated the relationship between DMARDs and dementia in patients with RA. METHODS: Using the National Health Insurance Research Database, patients aged ≥20years, who were newly diagnosed with RA between 2000 and 2011 were identified. Patients with RA who had dementia comprised the dementia group, and patients with RA who did not have dementia comprised the control group. The groups were matched at a 1:1 ratio by the propensity score. DMARDs were categorized into conventional synthetic DMARDs (csDMARDs) and biological DMARDs (bDMARDs). Logistic regression models were used to calculate the odds ratio and 95% confidence interval (CI) to evaluate the association between DMARD use and the risk of dementia in patients with RA. RESULTS: A total of 957 patients with RA and dementia, and 957 patients with RA but not dementia, were enrolled. The risk of dementia was determined to be 1.63-fold higher in patients with RA with csDMARD use than in those without csDMARD use (95% CI=1.33-2.00). No significant risk of dementia was observed in patients with RA who used bDMARDs compared with their counterparts. However, patients with RA who used hydroxychloroquine, methotrexate, and sulfasalazine exhibited significant risks of dementia, irrespective of cumulative exposure days. CONCLUSION: Patients with RA who used csDMARDs exhibit significant association with dementia.
BACKGROUND:Patients with rheumatoid arthritis (RA) exhibit an increased risk of dementia. Disease-modifying antirheumatic drugs (DMARDs) are commonly used to slow RA progression, but studies investigating the relationship between DMARDs and dementia in patients with RA are lacking. We investigated the relationship between DMARDs and dementia in patients with RA. METHODS: Using the National Health Insurance Research Database, patients aged ≥20years, who were newly diagnosed with RA between 2000 and 2011 were identified. Patients with RA who had dementia comprised the dementia group, and patients with RA who did not have dementia comprised the control group. The groups were matched at a 1:1 ratio by the propensity score. DMARDs were categorized into conventional synthetic DMARDs (csDMARDs) and biological DMARDs (bDMARDs). Logistic regression models were used to calculate the odds ratio and 95% confidence interval (CI) to evaluate the association between DMARD use and the risk of dementia in patients with RA. RESULTS: A total of 957 patients with RA and dementia, and 957 patients with RA but not dementia, were enrolled. The risk of dementia was determined to be 1.63-fold higher in patients with RA with csDMARD use than in those without csDMARD use (95% CI=1.33-2.00). No significant risk of dementia was observed in patients with RA who used bDMARDs compared with their counterparts. However, patients with RA who used hydroxychloroquine, methotrexate, and sulfasalazine exhibited significant risks of dementia, irrespective of cumulative exposure days. CONCLUSION:Patients with RA who used csDMARDs exhibit significant association with dementia.
Authors: Maria Vassilaki; Cynthia S Crowson; John M Davis Iii; Stephanie Q Duong; David T Jones; Aivi Nguyen; Michelle M Mielke; Prashanthi Vemuri; Elena Myasoedova Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Chunlei Zheng; Nathanael R Fillmore; Jaime Ramos-Cejudo; Mary Brophy; Ricardo Osorio; Mark E Gurney; Wei Qiao Qiu; Rhoda Au; George Perry; Maureen Dubreuil; Shu G Chen; Xin Qi; Pamela B Davis; Nhan Do; Rong Xu Journal: Alzheimers Dement Date: 2021-09-27 Impact factor: 16.655
Authors: Danielle Newby; Daniel Prieto-Alhambra; Talita Duarte-Salles; David Ansell; Lars Pedersen; Johan van der Lei; Mees Mosseveld; Peter Rijnbeek; Glen James; Myriam Alexander; Peter Egger; Jana Podhorna; Robert Stewart; Gayan Perera; Paul Avillach; Solène Grosdidier; Simon Lovestone; Alejo J Nevado-Holgado Journal: Alzheimers Res Ther Date: 2020-04-06 Impact factor: 6.982
Authors: Vanessa L Kronzer; Cynthia S Crowson; John M Davis; Maria Vassilaki; Michelle M Mielke; Elena Myasoedova Journal: Semin Arthritis Rheum Date: 2021-06-15 Impact factor: 5.431